Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2009

View Archived Issues

Array BioPharma discovers oncolytic checkpoint kinase inhibitors

Case control analysis reveals reduced AD risk with IV immunoglobulin

Enhanced fibrinolytic potency seen with reprogrammed streptokinases

Riluzole modulates alcohol self-administration and withdrawal in preclinical studies

Liraglutide safe and effective in combination with metformin and rosiglitazone

Astellas Pharma reports first quarter FY2009 results

Rifaximin accepted for filing and granted priority review by FDA

BrainStorm receives funding for ALS research trials

Nanotherapeutics awarded NIAID contract to develop inhaled smallpox antiviral

PharmaGap reports NCI results from GAP-107-B-8 testing

Regado enrolls first patient in phase I trial of anticoagulant REG1 System

R-Tech Ueno completes enrollment in phase II UF-021 study

Phase III Urocidin trial cleared to continue by DMC

Loramyc marketing authorization granted in Switzerland

Wyeth to continue liver X receptor target program initiated by Karo Bio

T-type calcium channel antagonist TTA-A8 a clinical candidate for sleep disorders

Preclinical characteristics of antidiabetic candidate canagliflozin described

GSK presents preclinical data on novel S1P1 agonist, PPI-4955, at recent ACS meeting

Shire designs prodrugs of mu opioid receptor ligands for pain treatment

Monoamine neurotransmitter reuptake inhibitors described by NeuroSearch

Bayer Schering Pharma identifies novel compounds acting on Toll-like receptors

Wisconsin Alumni Research Foundation describes VDR ligands for skin conditions

Bayer Schering Pharma claims novel MR antagonists, PR and AR agonists

Enrollment in phase IIa trial of ALV-003 for celiac disease started

Gene-based medicine for refractory angina enters phase I/IIa clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...